Lactylation Antibodies: Decoding the Cross-Talk Between Tumor Metabolism and Immunity with ANT BIO PTE. LTD.

The intersection of metabolism and epigenetics has emerged as a pivotal frontier in cancer research, revealing how metabolic reprogramming shapes epigenetic landscapes to drive tumor progression, immune escape, and therapy resistance. Histone lactylation, an innovative epigenetic modification, stands at the center of this cross-talk—linking lactate, a key metabolite of tumor glycolysis, to the regulation of gene expression. This modification has become a critical target for understanding the molecular mechanisms underlying tumorigenesis and developing novel therapeutic strategies. Lactylation-specific antibodies, as precise tools for detecting and analyzing this modification, are indispensable for unlocking its biological functions. ANT BIO PTE. LTD., a global leader in life science reagents, offers state-of-the-art lactylation antibody products under its Starter sub-brand—engineered for exceptional modification specificity, broad recognition capability, and high affinity. These antibodies empower researchers to dissect the complex dialogue between tumor metabolism and immunity, explore lactylation-mediated disease mechanisms, and accelerate the development of targeted cancer therapies. This article delves into the molecular nature of histone lactylation, the technical advantages of lactylation antibodies, their role in tumor biology, and the outstanding value of ANT BIO PTE. LTD.’s products in advancing this cutting-edge research field.

What is Histone Lactylation? Core Concept and Research Significance

Histone lactylation is an emerging reversible epigenetic modification defined by the covalent attachment of a lactate group to specific lysine residues on the N-terminal tails of histones via an amide bond. Key identified modification sites include H3K18, H3K27, H4K5, and H4K8, among others. This modification is catalyzed by enzymes with lactyltransferase activity—notably, acetyltransferases such as p300/CBP, which have been found to transfer metabolically generated lactate molecules to histone targets.

The research significance of histone lactylation is profound, as it bridges cellular metabolism and epigenetic regulation:

• Gene expression modulation: Lactylation primarily enriches in gene promoter and enhancer regions, altering chromatin spatial conformation to promote the transcriptional activation of target genes. These genes are involved in critical biological processes such as immunosuppressive pathways, cell survival and migration, extracellular matrix remodeling, and resistance to cell death—all central to tumor progression.
• Metabolism-epigenetics cross-talk: Lactylation serves as a direct molecular link between cellular metabolic status (e.g., glycolytic activity and lactate accumulation) and epigenetic regulation, enabling tumors to adapt to the hypoxic tumor microenvironment (TME) and drive malignant progression.
• Therapeutic potential: Given its role in tumor immune escape and therapy resistance, lactylation has emerged as a promising target for the development of novel anti-cancer strategies, including combinations of metabolic inhibitors and immunotherapy.

In the context of cancer research, lactylation antibodies are essential for decoding this dynamic modification and translating basic discoveries into clinical applications.

Research Frontiers: Lactylation Antibodies in Tumor Metabolism and Immunity

Lactylation research is rapidly evolving, with lactylation antibodies at the forefront of key advancements in understanding tumor biology and developing targeted therapies. The current research frontiers include:

1. Single-cell and spatial lactylation analysis: Antibodies optimized for low-input samples enable the characterization of lactylation heterogeneity across different tumor cell subsets and within the TME, revealing cell-type-specific metabolic-epigenetic signatures.
2. Multi-omics integration: Combining lactylation data from ChIP-seq/CUT&Tag with transcriptomics, metabolomics, and proteomics to build comprehensive regulatory networks, uncovering how lactylation coordinates metabolic reprogramming and gene expression in tumors.
3. Therapeutic target validation: Using lactylation antibodies to validate the efficacy of metabolic inhibitors (e.g., lactate dehydrogenase inhibitors) and epigenetic modulators in preclinical models, accelerating the development of combination therapies.
4. Clinical translational research: Developing lactylation-based biomarkers for patient stratification, prognosis assessment, and monitoring of treatment response in clinical trials.

ANT BIO PTE. LTD.’s lactylation antibodies are designed to meet these cutting-edge research needs, combining high specificity, sensitivity, and multi-platform compatibility to drive breakthroughs in basic and translational cancer research.

Mechanisms & Biological Roles: How Lactylation Drives Tumor Progression

Lactylation exerts profound effects on tumor biology by regulating key pathways involved in immune escape and therapy resistance—processes that are critical for tumor survival and progression. Below is a detailed breakdown of these mechanisms and the role of lactylation antibodies in their investigation.

1. Molecular Mechanism of Histone Lactylation

The lactylation process is tightly linked to cellular metabolism and enzymatic activity:

• Lactate production: Tumor cells exhibit enhanced glycolysis (Warburg effect) even under normoxic conditions, leading to the accumulation of lactate in the cytoplasm and TME.
• Lactyltransferase activity: Enzymes such as p300/CBP catalyze the transfer of lactate groups from lactate to specific lysine residues on histones, forming lactylated histone derivatives.
• Transcriptional activation: Lactylation alters chromatin structure, increasing accessibility to transcription factors and promoting the expression of genes involved in tumor progression, immune suppression, and therapy resistance.

Lactylation antibodies enable the detection of this modification at the molecular level, providing insights into its dynamic regulation and functional consequences.

2. Lactylation-Mediated Tumor Immune Escape

In the TME, lactylation promotes tumor immune escape through a well-characterized mechanism, as demonstrated in glioblastoma and other cancer models:

• Lactate accumulation in cancer stem cells: Elevated lactate levels enhance histone lactylation, which in turn upregulates the expression of the immune checkpoint molecule CD47 via the CBX3-EP300 complex.
• CD47-mediated "don't eat me" signal: CD47 binds to signal regulatory protein α (SIRPα) on macrophages, inhibiting phagocytosis of tumor cells and enabling immune escape.
• Therapeutic potential: Experimental evidence shows that sodium lactate treatment reduces macrophage-mediated tumor cell phagocytosis, while the lactate dehydrogenase inhibitor dichloroacetate (DCA) reverses this effect. Combination therapy with DCA and anti-CD47 antibodies exhibits synergistic anti-tumor effects in animal models, significantly inhibiting tumor growth and prolonging survival.

Lactylation antibodies (e.g., pan-lactylation and H3K18la antibodies) are critical for verifying this mechanism, enabling the detection of lactylation levels, the identification of target genes (e.g., CD47), and the evaluation of therapeutic efficacy.

3. Lactylation and Therapy Resistance

Lactylation also plays a key role in mediating tumor resistance to therapy, as illustrated in studies of liver cancer metastasis after microwave ablation:

• Sublethal heat stress-induced glycolysis: Local therapy such as microwave ablation induces sublethal heat stress, enhancing tumor cell glycolysis and lactate accumulation.
• H3K18 lactylation upregulation: Increased lactate levels lead to elevated H3K18 lactylation, which specifically enriches at the NFS1 gene locus.
• Ferroptosis resistance and metastasis: Lactylation-mediated upregulation of NFS1 (a key factor in iron-sulfur cluster assembly) enhances cellular resistance to ferroptosis—a form of regulated cell death—and promotes tumor cell metastasis.
• Therapeutic implication: Knocking down NFS1 increases tumor cell sensitivity to oxaliplatin, and combined intervention suppresses metastasis in animal models, highlighting the potential of targeting lactylation to overcome therapy resistance.

Lactylation antibodies enable the detection of H3K18 lactylation and its association with NFS1 expression, providing a tool for studying therapy resistance mechanisms and developing combination treatment strategies.

Technical Advantages and Research Strategies of Lactylation Antibodies

Lactylation-specific antibodies are specialized tools designed to meet the unique challenges of detecting this modification, with technical advantages that support diverse research applications. A multi-level research strategy leveraging these antibodies is essential for decoding the biological functions of lactylation.

1. Technical Advantages of Lactylation Antibodies

Lactylation antibodies are available in two primary categories, each with distinct strengths to support comprehensive research:

• Pan-lactylation antibodies: Detect global changes in lactylation levels across all proteins, providing an overall view of modification dynamics in response to metabolic or environmental cues.
• Site-specific lactylation antibodies: Precisely target specific lactylation sites (e.g., H3K18la, H3K27la), enabling the localization of dynamic changes at individual residues and mechanistic analysis of their biological functions.

These antibodies are compatible with a range of key experimental platforms:

• Western Blot (WB): Enables semi-quantitative analysis of lactylation levels in cell lysates or tissue samples.
• Immunofluorescence (IF) and Immunohistochemistry (IHC): Visualizes the spatial distribution of lactylation within cells and tissues, revealing its localization in the nucleus (chromatin) and its association with tumor cell subsets.
• Chromatin Immunoprecipitation sequencing (ChIP-seq) and CUT&Tag: Identifies the genomic localization of lactylation modifications and their association with gene expression, uncovering target genes regulated by lactylation.
• Immunoprecipitation (IP) combined with mass spectrometry (MS): Discovers novel lactylation sites and interacting proteins, expanding the understanding of lactylation regulatory networks.

2. Key Strategies for Lactylation Research

A multi-level integrated strategy is recommended for lactylation research, leveraging lactylation antibodies to link metabolism, epigenetics, and function:

• Metabolic level: Use Seahorse analysis and metabolomics to quantify glycolytic capacity and lactate levels, establishing a link between metabolic status and lactylation.
• Epigenetic level: Employ pan-lactylation and site-specific antibodies to detect modification changes, combined with ChIP-seq/CUT&Tag to map genomic enrichment regions and identify target genes.
• Functional level: Design intervention experiments (e.g., lactate treatment, metabolic inhibitors, gene knockdown/overexpression) to validate the role of lactylation in tumor phenotypes such as immune escape and therapy resistance.
• Mechanistic level: Focus on hub regulatory factors (e.g., p300/CBP, CBX3) and use techniques such as site-directed mutagenesis, protein-protein interaction assays, and subcellular localization to decipher their roles in the lactylation network.

Clinical Significance of Lactylation Research

Lactylation research holds significant clinical translational value, with potential applications in cancer diagnosis, prognosis, and therapy:

• Biomarker development: Lactylation levels (e.g., H3K18la) correlate with poor prognosis in various tumors, making them promising biomarkers for patient risk stratification and prognosis assessment.
• Therapeutic strategy development: Intervention targeting the lactylation pathway—such as combining metabolic inhibitors (e.g., DCA) with immune checkpoint inhibitors (e.g., anti-CD47 antibodies) or chemotherapy—offers new directions for combination therapy, addressing unmet clinical needs in cancer treatment.
• Clinical trial monitoring: Lactylation antibodies can be used to monitor the pharmacodynamic effects of metabolic and epigenetic therapies in clinical trials, ensuring target engagement and optimizing treatment regimens.

Future research will focus on validating the clinical value of lactylation through multi-center cohorts, translating basic discoveries into clinically applicable biomarkers and targeted therapies.

Product Application: ANT BIO PTE. LTD.’s Lactylation Antibodies – Precision Tools for Metabolic Epigenetics Research

ANT BIO PTE. LTD. offers a comprehensive portfolio of high-performance lactylation antibodies, including the flagship L-Lactyl Lysine Rabbit Polyclonal Antibody (Catalog No.: S0B0719) and the Histone H3 (Lactyl K9) Recombinant Rabbit mAb (S-R397, Catalog No.: S0B0756). These products are engineered for exceptional modification specificity, broad recognition capability, and high affinity—validated across key platforms including IP, WB, IF, and ChIP-seq/CUT&Tag. They are ideal tools for exploring the cross-talk between tumor metabolism and immunity, gene expression regulation, and disease mechanism research.

Core Advantages of ANT BIO PTE. LTD.’s Lactylation Antibodies

1. Ultra-High Modification Specificity: Cross-validated with modified and non-modified peptides, these antibodies specifically recognize L-lactylation modifications on lysine residues with minimal cross-reactivity to other common acylations (e.g., acetylation, crotonylation)—ensuring accurate detection of lactylation in complex biological samples.
2. Broad Recognition Capability: The polyclonal nature of the L-Lactyl Lysine Antibody enables recognition of lactylation modifications across different protein backgrounds (histones and non-histone proteins), providing wide coverage for discovery research.
3. Excellent Affinity and Sensitivity: These antibodies exhibit high affinity for lactylated targets, enabling efficient enrichment and detection of endogenous lactylated proteins—even in low-abundance samples such as primary tumor tissues.
4. Superior Batch Consistency: Manufactured under stringent quality control standards, with strict serum pool management and purification processes ensuring consistent performance across different batches—providing reliable support for long-term research projects and multi-laboratory collaborations.

Key Application Scenarios

ANT BIO PTE. LTD.’s lactylation antibodies are indispensable tools for a wide range of research areas in metabolic epigenetics and cancer biology:

• Metabolism-Epigenetics Cross-Talk Research: Explore how lactate acts as a signaling molecule to regulate cell function via protein lactylation, linking cellular metabolism to epigenetic states.
• Tumor Immunity and Immune Escape: Study the role of lactylation in immunometabolic reprogramming (e.g., macrophage polarization) and the TME, uncovering mechanisms of tumor immune escape.
• Gene Expression and Chromatin Regulation: Identify lactylation sites on histones and investigate their functions in transcriptional activation and chromatin dynamics.
• Disease Mechanism and Biomarker Discovery: Explore aberrant protein lactylation in tumors, metabolic diseases, and infectious diseases, and validate lactylation as a prognostic or diagnostic biomarker.
• Therapeutic Target Validation: Evaluate the efficacy of metabolic inhibitors, epigenetic modulators, and combination therapies in preclinical models, accelerating drug development.

Professional Technical Support

ANT BIO PTE. LTD. provides comprehensive technical support for all lactylation antibody products, including:

• Detailed technical documentation, including specificity validation data, standardized protocols for WB, IF, IP, and ChIP-seq/CUT&Tag, and a recommended target list.
• One-on-one professional consultation with metabolic epigenetics experts to assist with experimental design, troubleshooting, and result interpretation.
• Sample testing options to validate antibody performance with your specific experimental system before full purchase.

Related Lactylation Antibody Products from ANT BIO PTE. LTD.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.

Disclaimer

This article was partially created with the assistance of artificial intelligence. If any content involves copyright or intellectual property issues, please inform us, and we promise to verify and remove it immediately.